Kayne Anderson Rudnick Investment Management
GSK icon

Kayne Anderson Rudnick Investment Management’s GSK GSK Stock Holding History

Kayne Anderson Rudnick Investment Management’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$700K Sell
13,345
-2,523
-16% -$133K ﹤0.01% 450
2026
Q1 		$876K Sell
15,868
-164
-1% -$8.89K ﹤0.01% 391
2025
Q4 		$786K Sell
16,032
-1,419
-8% -$66.2K ﹤0.01% 418
2025
Q3 		$753K Buy
17,451
+3,502
+25% +$137K ﹤0.01% 406
2025
Q2 		$536K Buy
13,949
+443
+3% +$16.9K ﹤0.01% 426
2025
Q1 		$523K Sell
13,506
-156
-1% -$5.71K ﹤0.01% 417
2024
Q4 		$462K Sell
13,662
-2,196
-14% -$79.1K ﹤0.01% 415
2024
Q3 		$648K Sell
15,858
-3,488
-18% -$143K ﹤0.01% 401
2024
Q2 		$745K Sell
19,346
-682
-3% -$28.7K ﹤0.01% 405
2024
Q1 		$859K Sell
20,028
-1,291
-6% -$53.2K ﹤0.01% 380
2023
Q4 		$790K Sell
21,319
-361
-2% -$13K ﹤0.01% 379
2023
Q3 		$786K Buy
21,680
+886
+4% +$31.4K ﹤0.01% 377
2023
Q2 		$741K Buy
20,794
+535
+3% +$19.2K ﹤0.01% 376
2023
Q1 		$721K Sell
20,259
-235
-1% -$8.22K ﹤0.01% 369
2022
Q4 		$720K Buy
20,494
+2,473
+14% +$82.4K ﹤0.01% 375
2022
Q3 		$530K Sell
18,021
-1,593
-8% -$60.4K ﹤0.01% 372
2022
Q2 		$1.07M Buy
19,614
+78
+0.4% +$4.31K ﹤0.01% 345
2022
Q1 		$1.06M Sell
19,536
-373
-2% -$20.3K ﹤0.01% 336
2021
Q4 		$1.1M Sell
19,909
-111
-0.6% -$5.77K ﹤0.01% 338
2021
Q3 		$956K Buy
20,020
+547
+3% +$27.5K ﹤0.01% 336
2021
Q2 		$969K Sell
19,473
-1,174
-6% -$56.4K ﹤0.01% 334
2021
Q1 		$921K Sell
20,647
-255,274
-93% -$11.6M ﹤0.01% 323
2020
Q4 		$12.7M Sell
275,921
-34,795
-11% -$1.6M 0.04% 216
2020
Q3 		$14.6M Buy
310,716
+145,673
+88% +$7.3M 0.05% 186
2020
Q2 		$8.41M Sell
165,043
-5,696
-3% -$292K 0.04% 201
2020
Q1 		$8.09M Buy
170,739
+6,229
+4% +$332K 0.05% 190
2019
Q4 		$9.66M Sell
164,510
-93,388
-36% -$5.19M 0.05% 182
2019
Q3 		$13.8M Sell
257,898
-9,913
-4% -$510K 0.07% 158
2019
Q2 		$13.4M Buy
267,811
+19,908
+8% +$999K 0.07% 151
2019
Q1 		$12.9M Buy
247,903
+9,256
+4% +$463K 0.07% 146
2018
Q4 		$11.4M Sell
238,647
-36,471
-13% -$1.8M 0.08% 150
2018
Q3 		$13.8M Sell
275,118
-3,256
-1% -$165K 0.08% 149
2018
Q2 		$14M Sell
278,374
-82,079
-23% -$4.13M 0.09% 149
2018
Q1 		$17.6M Buy
360,453
+65,015
+22% +$3.03M 0.13% 132
2017
Q4 		$13.1M Sell
295,438
-41,621
-12% -$1.92M 0.11% 158
2017
Q3 		$17.1M Sell
337,059
-11,049
-3% -$561K 0.15% 136
2017
Q2 		$18.8M Buy
348,108
+38,629
+12% +$2.06M 0.19% 126
2017
Q1 		$16.3M Buy
309,479
+53,355
+21% +$2.71M 0.18% 141
2016
Q4 		$12.3M Sell
256,124
-13,907
-5% -$687K 0.15% 158
2016
Q3 		$14.6M Buy
270,031
+199,636
+284% +$10.9M 0.18% 148
2016
Q2 		$3.81M Buy
70,395
+981
+1% +$51.7K 0.06% 185
2016
Q1 		$3.52M Sell
69,414
-2,650
-4% -$132K 0.06% 176
2015
Q4 		$3.63M Sell
72,064
-9,486
-12% -$484K 0.06% 176
2015
Q3 		$3.92M Buy
81,550
+3,496
+4% +$182K 0.07% 172
2015
Q2 		$4.06M Buy
78,054
+7,607
+11% +$428K 0.06% 174
2015
Q1 		$4.06M Buy
70,447
+16,063
+30% +$921K 0.06% 175
2014
Q4 		$2.9M Buy
54,384
+12,247
+29% +$685K 0.05% 192
2014
Q3 		$2.42M Buy
42,137
+8,455
+25% +$518K 0.04% 193
2014
Q2 		$2.25M Buy
33,682
+4,520
+15% +$306K 0.04% 201
2014
Q1 		$1.95M Buy
29,162
+3,863
+15% +$261K 0.03% 204
2013
Q4 		$1.69M Buy
25,299
+4,531
+22% +$294K 0.03% 208
2013
Q3 		$1.3M Buy
20,768
+1,405
+7% +$90.4K 0.02% 208
2013
Q2 		$1.21M Buy
+19,363
New +$1.23M 0.02% 207

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management's GSK Position: Q2 2026 in Review

Kayne Anderson Rudnick Investment Management reduced its GSK (GSK) stake by 16% in Q2 2026, selling an estimated $133K and leaving 13,345 shares worth $700K. The position accounts for ﹤0.01% of the portfolio, ranked #450.

Kayne Anderson Rudnick Investment Management first reported a position in GSK in Q2 2013 and has held it in 53 quarters since. The position peaked at $18.8M in Q2 2017. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

  • Kayne Anderson Rudnick Investment Management held 13,345 shares of GSK worth $700K as of Q2 2026.
  • Kayne Anderson Rudnick Investment Management sold 2,523 GSK shares in Q2 2026, an estimated $133K.
  • GSK made up ﹤0.01% of Kayne Anderson Rudnick Investment Management's portfolio in Q2 2026, its #450 holding.
  • Kayne Anderson Rudnick Investment Management first reported a position in GSK in Q2 2013 and has held it in 53 quarters since.
  • Kayne Anderson Rudnick Investment Management's GSK position peaked at $18.8M in Q2 2017.
  • 1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Kayne Anderson Rudnick Investment Management's 13F filing for Q2 2026, filed 13 Aug 2026.